Sonoma Pharmaceuticals (SNOA) Competitors $2.63 +0.08 (+3.14%) (As of 12/20/2024 05:23 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends SNOA vs. CARA, ACXP, MRNS, TXMD, HCWB, AIM, PMCB, SLGL, WENA, and AWHShould you be buying Sonoma Pharmaceuticals stock or one of its competitors? The main competitors of Sonoma Pharmaceuticals include Cara Therapeutics (CARA), Acurx Pharmaceuticals (ACXP), Marinus Pharmaceuticals (MRNS), TherapeuticsMD (TXMD), HCW Biologics (HCWB), AIM ImmunoTech (AIM), PharmaCyte Biotech (PMCB), Sol-Gel Technologies (SLGL), ANEW Medical (WENA), and Aspira Women's Health (AWH). These companies are all part of the "pharmaceutical products" industry. Sonoma Pharmaceuticals vs. Cara Therapeutics Acurx Pharmaceuticals Marinus Pharmaceuticals TherapeuticsMD HCW Biologics AIM ImmunoTech PharmaCyte Biotech Sol-Gel Technologies ANEW Medical Aspira Women's Health Cara Therapeutics (NASDAQ:CARA) and Sonoma Pharmaceuticals (NASDAQ:SNOA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, community ranking, media sentiment, risk, profitability, analyst recommendations and dividends. Does the MarketBeat Community prefer CARA or SNOA? Cara Therapeutics received 451 more outperform votes than Sonoma Pharmaceuticals when rated by MarketBeat users. Likewise, 72.74% of users gave Cara Therapeutics an outperform vote while only 67.50% of users gave Sonoma Pharmaceuticals an outperform vote. CompanyUnderperformOutperformCara TherapeuticsOutperform Votes66772.74% Underperform Votes25027.26% Sonoma PharmaceuticalsOutperform Votes21667.50% Underperform Votes10432.50% Do insiders and institutionals believe in CARA or SNOA? 44.7% of Cara Therapeutics shares are held by institutional investors. Comparatively, 2.0% of Sonoma Pharmaceuticals shares are held by institutional investors. 3.1% of Cara Therapeutics shares are held by insiders. Comparatively, 3.9% of Sonoma Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Do analysts rate CARA or SNOA? Cara Therapeutics presently has a consensus target price of $2.32, indicating a potential upside of 448.98%. Given Cara Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Cara Therapeutics is more favorable than Sonoma Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cara Therapeutics 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Sonoma Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has stronger earnings & valuation, CARA or SNOA? Sonoma Pharmaceuticals has higher revenue and earnings than Cara Therapeutics. Sonoma Pharmaceuticals is trading at a lower price-to-earnings ratio than Cara Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCara Therapeutics$8.69M2.67-$118.51M-$1.75-0.24Sonoma Pharmaceuticals$13.55M0.26-$4.84M-$4.99-0.53 Is CARA or SNOA more profitable? Sonoma Pharmaceuticals has a net margin of -27.21% compared to Cara Therapeutics' net margin of -1,099.76%. Sonoma Pharmaceuticals' return on equity of -59.58% beat Cara Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cara Therapeutics-1,099.76% -367.97% -107.43% Sonoma Pharmaceuticals -27.21%-59.58%-24.33% Which has more risk & volatility, CARA or SNOA? Cara Therapeutics has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500. Comparatively, Sonoma Pharmaceuticals has a beta of 1.43, indicating that its stock price is 43% more volatile than the S&P 500. Does the media prefer CARA or SNOA? In the previous week, Cara Therapeutics had 7 more articles in the media than Sonoma Pharmaceuticals. MarketBeat recorded 8 mentions for Cara Therapeutics and 1 mentions for Sonoma Pharmaceuticals. Cara Therapeutics' average media sentiment score of 0.31 beat Sonoma Pharmaceuticals' score of 0.00 indicating that Cara Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cara Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sonoma Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryCara Therapeutics beats Sonoma Pharmaceuticals on 10 of the 17 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Get Sonoma Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SNOA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNOA vs. The Competition Export to ExcelMetricSonoma PharmaceuticalsSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.52M$4.34B$5.14B$9.08BDividend YieldN/A44.57%5.09%4.23%P/E Ratio-0.5325.3790.0517.18Price / Sales0.2645.921,117.14116.99Price / CashN/A43.4443.0437.86Price / Book0.337.094.784.78Net Income-$4.84M$13.64M$120.31M$225.60M7 Day Performance-1.50%-2.93%-1.92%-1.23%1 Month Performance-9.62%0.28%11.51%3.36%1 Year Performance1,608.90%40.76%30.61%16.60% Sonoma Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNOASonoma Pharmaceuticals0.5865 of 5 stars$2.63+3.1%N/A+1,658.0%$3.52M$13.55M-0.53180CARACara Therapeutics4.2221 of 5 stars$0.26-1.5%$2.32+799.2%-30.3%$14.15M$8.69M-0.1555News CoverageGap DownACXPAcurx Pharmaceuticals1.3965 of 5 stars$0.83-3.5%$12.00+1,354.5%-76.4%$13.94MN/A-0.783Gap UpMRNSMarinus Pharmaceuticals4.3119 of 5 stars$0.25-7.5%$4.79+1,832.1%-97.5%$13.67M$31.47M-0.10110Analyst ForecastNews CoverageTXMDTherapeuticsMD0.4367 of 5 stars$1.18-3.3%N/A-51.9%$13.61M$1.30M0.00420Analyst ForecastGap UpHigh Trading VolumeHCWBHCW Biologics0.4079 of 5 stars$0.36-0.4%N/A-62.9%$13.44M$3.50M-0.3640Gap DownAIMAIM ImmunoTech2.3707 of 5 stars$0.21-4.1%$2.75+1,209.5%-60.8%$13.39M$190,000.00-0.4720PMCBPharmaCyte Biotech0.9032 of 5 stars$1.69-1.7%N/A-26.8%$12.98MN/A2.612Earnings ReportSLGLSol-Gel Technologies2.4264 of 5 stars$0.45-6.2%$5.00+1,006.2%-65.7%$12.59M$1.55M-1.3650WENAANEW MedicalN/A$0.73-0.5%N/AN/A$12.51MN/A0.00N/AGap UpAWHAspira Women's Health1.3425 of 5 stars$0.75+0.0%$4.40+486.7%-70.6%$12.50M$9.15M-0.62110Analyst Forecast Related Companies and Tools Related Companies Cara Therapeutics Competitors Acurx Pharmaceuticals Competitors Marinus Pharmaceuticals Competitors TherapeuticsMD Competitors HCW Biologics Competitors AIM ImmunoTech Competitors PharmaCyte Biotech Competitors Sol-Gel Technologies Competitors ANEW Medical Competitors Aspira Women's Health Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SNOA) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sonoma Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sonoma Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SNOA Stock Alerts